Collapse of AbbVie-Shire Deal Leaves Scars

The likely collapse of AbbVie’s $54 billion deal to buy Shire leaves two global drug companies in need of new, independent courses and investors and Wall Street bankers smarting from losses and fees they won’t collect.



from WSJ.com: US Business http://ift.tt/102u174

via IFTTT